📣 Second Presidential Symposium
#ESMO26

👉🏽 Ivonescimab plus chemotherapy versus durvalumab plus chemotherapy as first-line treatment for advanced biliary tract cancer: A randomized, controlled, double-blinded, phase 3 trial (HARMONi-GI1)

🗣️ Dr. Zhou
📌 PFS 8.4 vs 5.8m HR 0.61
📌 OS 14.9 vs 12.1m HR 0.75
☣️ Most frequent hematologic, AST elevation, proteinuria
☣️ Grade 3 or higher 82 vs 72%

@OncoAlert @myESMO @ASCO @_SEOM @UTMDAnderson @NEJM @brunolarvol
👇🏽👇🏽